There have been two previous Total Therapy studies for multiple myeloma (MM) at the Myeloma
Institute for Research and Therapy (MIRT): Total Therapy I (from 1989 through 1994) and Total
Therapy II (from 1996 to 2004). Results have shown that patients treated on these studies had
better outcomes (meaning patients have lived longer and had better responses to treatment)
when compared to patients treated with standard chemotherapy.
With this new study, Total Therapy III, researchers will take what they have learned from the
first two studies and add new treatment strategies to try to improve the outcomes even more,
especially for patients with chromosome abnormalities.